Psychotic Disorders Overview
Characterized by significant impairment in thought processes, perception, and emotional regulation.
Major Types:
Schizotypal Personality Disorder
Discomfort in close relationships.
Cognitive or perceptual distortions, including magical thinking (e.g. telepathy).
Ideas of reference and odd thinking/speaking.
Delusional Disorder
More than one month of delusions.
Key characteristics: falsity of beliefs, resistant to change.
Can feature bizarre delusions such as thought insertion or broadcasting.
Brief Psychotic Disorder
Episode lasts less than one month with at least one symptom of schizophrenia.
Resembles an emotional breakdown.
Schizophreniform Disorder
Symptoms meet schizophrenia criteria but last less than six months.
Schizophrenia
Required criteria: Two or more symptoms present for over six months, including delusions, hallucinations, and disorganized behavior.
Schizoaffective Disorder
Meets criteria for both schizophrenia and mood disorders (either MDD or BPD).
Delusions
Definition: a false belief that remains unchanged despite contradictory evidence.
Types of delusions:
Bizarre delusions (implausible).
Examples:
Thought insertion: Others are inserting thoughts.
Thought broadcasting: Belief that thoughts are accessible to others.
External control: Belief that thoughts are controlled externally.
Cultural Considerations:
Culturally held beliefs, even if bizarre, do not qualify as a disorder if generally accepted within that culture (e.g., Koro, Wendigo).
Diagnosis Criteria
No requirements of functional impairments other than delusions.
Delusions can be tactile/olfactory if related to the delusion.
Must specify type: erotomanic, grandiose, jealous, persecutory, somatic, mixed, unspecified.
Diagnostic Criteria
Two or more symptoms prolonged for at least six months, including:
Delusions.
Hallucinations.
Disorganized speech.
Grossly abnormal behavior (catatonia).
Negative symptoms.
Symptom Types:
Positive Symptoms: Hyperactivity of the mesolimbic system.
Includes delusions, hallucinations (predominantly auditory), and disorganized speech.
Negative Symptoms: Hypoactivity in the mesocortical system.
Affective flattening, alogia, avolition, apathy, anhedonia, attentional impairment.
Symptom Impact on Functioning:
Negative symptoms correlate more with real-world functioning than positive symptoms.
Prevalence: 70-83% of individuals experience hallucinations, predominantly auditory.
Types of Hallucinations:
Visual (30-57%).
Tactile, olfactory, gustatory (14-27%).
Symptom Presentation:
Paranoid, disorganized, or depressive presentations with varying symptoms and attitudes.
Psychotic symptoms can occur in various psychiatric disorders including bipolar disorder, major depression, schizoaffective disorder, and dementias like Alzheimer's and Lewy body dementia.
Delusional Disorder:
Rarity: 0.05-0.1%.
Heritability: 31-39%.
Schizophrenia:
Prevalence: Approximately 0.5%, equal gender distribution.
Heritability significant: 80% (high concordance in MZ twins compared to DZ twins).
Focus on Dopamine Pathways:
Mesolimbic Pathway: Involved in positive symptoms; D2 receptor blockade can reduce symptoms but may reduce motivation.
Mesocortical Pathway: Involved in negative symptoms; dysfunction can cause cognitive issues.
Nigrostriatal and Tuberoinfundibular Pathways: Related to motor side effects and prolactin secretion, respectively.
Serotonin's Role:
Influences dopamine release; modulation may help with treatment efficacy.
Types of Antipsychotics:
First-Generation (Typical): Primarily D2 blockers.
Second-Generation (Atypical): Block both DA and 5-HT2A, can be more effective for negative symptoms.
Key Antipsychotics Introduced:
Chlorpromazine (1950), Haloperidol (1958), Clozapine (1990), and others.
Elderly Patients with Dementia:
Increased risk of death, particularly from cardiac and cerebrovascular incidents.
Box warning for all antipsychotics when used in geriatric patients.
Evaluation of patient history and existing conditions to ensure correct diagnosis and treatment options.
Addressing possible non-compliance and understanding the therapeutic range and the time required for medication to take effect.